Loading
Every dated change on the records linked to KRAS G12C-mutant pancreatic ductal adenocarcinoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Objective response 21 percent (8 of 38; 95 percent confidence interval 10 to 37); median progression-free survival 4.
Pancreatic cancer cohort: objective response in 7 of 21 patients (33.
A milestone in how this cancer is treated.